What is the difference between aminophylline and theophylline?

Aminophylline is a salt of theophylline combined with ethylenediamine, containing approximately 80% theophylline by weight. Aminophylline is water-soluble and suitable for IV administration, while theophylline is used orally. The active component in both is theophylline. Dosing must account for the 80% conversion factor.

Why has caffeine replaced aminophylline as first-line for neonatal apnea?

Caffeine has a wider therapeutic index (fewer side effects at standard doses), longer half-life allowing once-daily dosing, better oral bioavailability, fewer drug interactions, and proven long-term neurodevelopmental benefits from the CAP trial. Routine therapeutic drug monitoring is not required for caffeine.

What is the loading dose of aminophylline for neonatal apnea?

The loading dose of aminophylline is 5-7 mg/kg IV administered over 20-30 minutes, equivalent to 4-5.6 mg/kg of theophylline. The maintenance dose is 1.5-3 mg/kg/dose every 8-12 hours IV or orally (as theophylline). Dosing intervals depend on gestational and postnatal age.

What is the therapeutic range for theophylline in neonates?

The therapeutic range for theophylline in neonates being treated for apnea is 5-12 mcg/mL (lower than the 10-20 mcg/mL range used for bronchospasm in older patients). Toxicity including tachycardia, vomiting, and seizures becomes more likely at levels above 15 mcg/mL in neonates.

When is aminophylline still used instead of caffeine in Indian NICUs?

Aminophylline is still used when caffeine citrate is unavailable, which may occur in rural and district hospital settings in India. It is also sometimes used in post-extubation apnea in term neonates and as an adjunct bronchodilator. IV aminophylline is more widely available than IV caffeine citrate in many Indian hospitals.

Aminophylline vs Theophylline Neonatal Apnea

Introduction to Methylxanthine Therapy in Neonates

Methylxanthines have been the pharmacological backbone for managing apnea of prematurity since the 1970s, when Kuzemko and Paala first described the use of theophylline for neonatal apnea. Three methylxanthines have been used in neonatal practice: theophylline (and its IV formulation, aminophylline), caffeine, and doxofylline. While caffeine citrate has become the preferred first-line agent in modern neonatal practice, aminophylline and theophylline remain clinically relevant in India, particularly in settings where caffeine citrate is unavailable or unaffordable.

This article provides a comprehensive comparison of aminophylline and theophylline for neonatal apnea management, covering pharmacology, dosing, therapeutic drug monitoring, safety profiles, and the clinical rationale for when these drugs may still be appropriately used in Indian NICUs. Understanding both the older and newer methylxanthines ensures that neonatal practitioners can provide effective care regardless of resource availability.

Pharmacology of Aminophylline and Theophylline

Relationship Between the Two Drugs

Aminophylline is the ethylenediamine salt of theophylline, containing approximately 80 percent theophylline by weight. The ethylenediamine component increases water solubility, making aminophylline suitable for IV administration, but it is ethylenediamine that is responsible for some adverse effects including local irritation and, rarely, allergic reactions. When aminophylline is administered intravenously, it is the theophylline component that exerts the therapeutic effect. For oral administration, theophylline is used directly. All therapeutic drug monitoring measures serum theophylline levels, regardless of whether aminophylline or theophylline is administered.

Mechanism of Action

Theophylline acts through multiple mechanisms relevant to neonatal apnea management. It competitively antagonizes adenosine receptors (A1 and A2), increasing central respiratory drive and chemoreceptor sensitivity to CO2. It inhibits phosphodiesterase enzymes, increasing intracellular cyclic AMP and enhancing diaphragmatic contractility. Theophylline also directly stimulates the medullary respiratory centre, increases calcium release from the sarcoplasmic reticulum of respiratory muscles, and has mild diuretic and bronchodilatory effects.

Neonatal Pharmacokinetics Comparison

Parameter	Theophylline (Neonates)	Caffeine (Neonates)
Half-life	12-58 hours (preterm), 6-12 hours (term)	40-230 hours (preterm), 40-100 hours (term)
Therapeutic range	5-12 mcg/mL	5-25 mcg/mL (caffeine base)
Toxic level	> 15 mcg/mL	> 40 mcg/mL
Therapeutic index	Narrow	Wide
Dosing frequency	Every 8-12 hours	Once daily
TDM requirement	Essential	Usually not needed
Oral bioavailability	75-90% (variable)	> 90% (consistent)
Interconversion	Partially metabolized to caffeine in neonates	Not significantly metabolized to theophylline

A unique pharmacokinetic feature in neonates is the N-methylation of theophylline to caffeine, a metabolic pathway not seen in adults. In preterm neonates, up to 50 percent of theophylline may be converted to caffeine, which contributes to the overall therapeutic effect but complicates drug level interpretation. This interconversion diminishes with postnatal maturation.

Dosing Protocols

Aminophylline (Intravenous)

Parameter	Preterm (< 32 weeks)	Late Preterm (32-36 weeks)	Term
Loading dose	5-6 mg/kg IV over 20 min	5-7 mg/kg IV over 20 min	5-7 mg/kg IV over 20 min
Maintenance dose	1.5-2 mg/kg q12h	2-2.5 mg/kg q8-12h	2-3 mg/kg q8h
Start maintenance	12 hours after loading	8-12 hours after loading	8 hours after loading

Theophylline (Oral)

Parameter	Preterm (< 32 weeks)	Late Preterm (32-36 weeks)	Term
Loading dose	4-5 mg/kg oral	4-5 mg/kg oral	4-5 mg/kg oral
Maintenance dose	1.5-2 mg/kg q12h	2-2.5 mg/kg q8-12h	2-3 mg/kg q8h
Formulation	Oral solution or crushed tablet	Oral solution or crushed tablet	Oral solution or tablet

Note: When converting from IV aminophylline to oral theophylline, reduce the dose by 20 percent to account for the ethylenediamine component in aminophylline (aminophylline dose multiplied by 0.8 equals the theophylline dose).

Therapeutic Drug Monitoring

Unlike caffeine, therapeutic drug monitoring is essential for theophylline due to its narrow therapeutic index. The difference between therapeutic and toxic levels is small, and individual pharmacokinetic variability in neonates makes dose-response prediction unreliable.

TDM Protocol

First trough level: Obtain 48 to 72 hours after initiating therapy (before the fifth or sixth dose at steady state).
Target range: 5 to 12 mcg/mL for apnea of prematurity.
Frequency: Weekly during stable therapy; more frequently during dose changes, illness, or drug interactions.
Peak levels: Not routinely required unless toxicity is suspected (obtain 1 to 2 hours after oral dose or 30 minutes after IV dose).

Dose Adjustment

Theophylline Level	Action
< 5 mcg/mL	Increase maintenance dose by 25%
5-12 mcg/mL	Therapeutic range; no change needed
12-15 mcg/mL	High therapeutic; monitor closely, consider reducing dose by 10-15%
15-20 mcg/mL	Hold one dose, reduce maintenance by 25%, recheck in 48 hours
> 20 mcg/mL	Hold all doses, monitor for toxicity, recheck levels, restart at reduced dose

Adverse Effects and Toxicity

Common Side Effects (Dose-Dependent)

Tachycardia: Heart rate above 180 bpm. Most common side effect and often the first sign of supratherapeutic levels.
Feeding intolerance: Gastroesophageal reflux, vomiting, and abdominal distension due to relaxation of the lower esophageal sphincter.
Jitteriness and irritability: CNS stimulation manifesting as restlessness and tremors.
Diuresis: Increased urine output that may contribute to dehydration if fluid intake is not adjusted.
Hyperglycemia: Mild elevation of blood glucose due to catecholamine stimulation.

Serious Toxicity (Levels > 15 mcg/mL)

Seizures: May occur at levels above 20 mcg/mL and can be life-threatening. Theophylline-induced seizures are often resistant to standard anticonvulsants.
Cardiac arrhythmias: Supraventricular tachycardia, ventricular ectopy at high levels.
Severe vomiting: Leading to aspiration risk, particularly in neonates with altered consciousness.
Metabolic derangements: Hypokalemia, hyperglycemia, metabolic acidosis.

Drug Interactions in the Neonatal Setting

Theophylline has numerous drug interactions that are clinically relevant in the NICU.

Phenobarbital: Induces hepatic metabolism of theophylline, potentially reducing levels. Monitor theophylline levels when phenobarbital is started or stopped.
Erythromycin and macrolides: Inhibit CYP1A2, increasing theophylline levels. Avoid combination or monitor levels closely.
Cimetidine: Reduces theophylline clearance by 40 percent. Use ranitidine as an alternative if H2 blockade is needed.
Fluconazole: Inhibits theophylline metabolism, increasing levels. Common interaction in NICUs where antifungal prophylaxis is used.

Why Caffeine Has Replaced Aminophylline

The shift from aminophylline and theophylline to caffeine citrate as the first-line methylxanthine for neonatal apnea is based on compelling evidence summarized below.

Wider therapeutic index: Caffeine's therapeutic range (5 to 25 mcg/mL) is substantially wider than theophylline's (5 to 12 mcg/mL), making it far safer with less risk of toxicity at standard doses.
Once-daily dosing: Caffeine's long half-life in preterm neonates allows once-daily dosing compared to two or three times daily for theophylline, reducing nursing workload and medication errors.
TDM not routinely required: Caffeine's wide therapeutic index and predictable pharmacokinetics make routine drug level monitoring unnecessary, a major advantage in Indian settings where TDM access may be limited.
CAP trial evidence: The large, randomized CAP trial demonstrated neurodevelopmental benefits of caffeine at 18 months and 5 years, with no comparable data for theophylline.
Fewer side effects: Caffeine causes less tachycardia, less GI upset, and fewer drug interactions than theophylline.

Current Role of Aminophylline in Indian NICUs

Despite caffeine's superiority, aminophylline retains a role in specific situations in Indian practice. In many district and sub-district hospitals and some government medical college NICUs, caffeine citrate may not be available due to procurement challenges. Aminophylline injection is more universally available across Indian hospitals and is included in the WHO Model List of Essential Medicines. In these settings, aminophylline remains a life-saving alternative for managing apnea of prematurity. HEAMAC clinical resource guides help facilities transition from aminophylline to caffeine-based protocols when supply chain improvements allow.

Conclusion

Aminophylline and theophylline are effective methylxanthines for neonatal apnea management that preceded the modern caffeine era. While caffeine citrate is now the clear first-line agent due to its superior safety profile and evidence base, understanding aminophylline and theophylline pharmacology remains essential for Indian neonatal practitioners, given the reality of variable drug availability across the country's healthcare system. When aminophylline or theophylline is used, strict attention to dosing, therapeutic drug monitoring, and toxicity surveillance is required to ensure safe and effective treatment.

Aminophylline vs Theophylline for Neonatal Apnea: Pharmacokinetics & Safety